What risks are older adults specifically more likely to face on Cosentyx (secukinumab)?
Cosentyx (secukinumab) is an immune-targeting drug that blocks interleukin-17A. The main risks tend to be the same as for younger adults, but older patients are more likely to experience them because they more often have age-related immune changes and coexisting conditions.
Key elderly-relevant risks include infection and problems that arise in people who already have comorbidities (such as chronic lung disease or diabetes). Cosentyx carries an infection risk in general, and clinicians are expected to be more cautious in patients who are older or otherwise higher-risk for infection.[1][2]
Does Cosentyx increase infection risk in seniors?
Cosentyx can increase the risk of infections, including serious infections, because it suppresses parts of the immune response.[1][2] This is the most clinically important “unique” issue for elderly patients in practice: the overall probability of infection is higher with age, even if the medication mechanism is the same.
In real-world prescribing, extra caution is usually warranted if an elderly patient has:
- A history of recurrent infections
- Diabetes, chronic kidney disease, or other immune-compromising conditions
- Chronic lung disease or frequent respiratory infections
What about serious infections like tuberculosis?
Cosentyx’s prescribing information includes guidance around tuberculosis (TB) screening and vigilance for TB during treatment (because biologic immune modulators can worsen latent infections). That matters for older adults too, since latent TB is more likely to go undetected in people with prior exposure.[1][2]
Are there any warning signs elderly patients should watch for?
Patients and caregivers are typically advised to seek medical attention promptly if they develop signs of infection while on Cosentyx, such as fever, worsening cough, shortness of breath, skin infections, or other unusual infections.[1][2] Older adults should be monitored closely because symptoms can be less typical or progress faster.
Is there anything “different” about safety in people 65+ versus younger patients?
Cosentyx safety information includes results from clinical studies and/or postmarketing experience, but the most practical age-related difference is not usually a brand-new type of adverse event that is exclusive to the elderly. Instead, older adults may have higher baseline risk for the drug’s known safety concerns (especially infections) and may have more concurrent medications that can complicate management.[1][2]
What other elderly factors can change the risk profile?
Cosentyx risk can shift depending on what else is going on clinically, including:
- Concurrent immunosuppressive medicines (additive infection risk)
- Frailty or reduced ability to recover from infection
- Vaccination status (live vaccines are generally an issue with immune-modifying therapies)
- Chronic heart, lung, or kidney disease (can make infections and other complications more dangerous)
These factors are patient-specific, but they are common in the elderly and therefore meaningfully affect real-world risk.[1][2]
How do doctors manage these risks in older patients?
Typical risk-reduction steps include:
- Screening for TB before starting, and reassessing if symptoms suggest TB later.[1][2]
- Evaluating infection history and current infection status before initiating therapy.[1][2]
- Ongoing monitoring during treatment for infection symptoms, and lowering the threshold to contact a clinician if symptoms appear.[1][2]
Are there alternatives if infection risk is a bigger concern in seniors?
If infection risk is too high, clinicians may adjust treatment strategy based on the patient’s condition (e.g., psoriatic arthritis vs. plaque psoriasis), disease severity, prior therapy response, and infection history. The right alternative depends on comorbidities and what is most dangerous for that individual patient.
If you tell me the patient’s age, indication (psoriasis vs. psoriatic arthritis vs. ankylosing spondylitis), current conditions (like diabetes/COPD), and other medications, I can narrow down which Cosentyx risks are most relevant.
---
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/ (FDA label access; use Cosentyx prescribing information)
[2] https://www.cosentyx.com/ (official product safety/label information)